[arista]

[The UK government has agreed to increase the
cost-effectiveness threshold for
new medicines by 25%, raising the upper limit
of the NICE quality-adjusted life year (QALY) threshold.

This is part of a deal to avoid US tariffs on
UK pharmaceuticals and may
lead to higher overall drug spending for the NHS.
The agreement also involves capping the rebates
pharmaceutical companies must pay back to
the NHS at 15%]


Was just Live on SkyNews